The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy

A. Chiappa, M. Makuuchi, N. J. Lygidakis, A. P. Zbar, G. Chong, E. Bertani, P. J. Sitzler, R. Biffi, U. Pace, P. P. Bianchi, G. Contino, P. Misitano, F. Orsi, L. Travaini, G. Trifirò, M. G. Zampino, N. Fazio, A. Goldhirsch, B. Andreoni

Research output: Contribution to journalArticle

Abstract

Colorectal cancer (CRC) caused nearly 204,000 deaths in Europe in 2004. Despite recent advances in the treatment of advanced disease, which include the incorporation of two new cytotoxic agents irinotecan and oxaliplatin into first-line regimens, the concept of planned sequential therapy involving three active agents during the course of a patient's treatment and the integrated use of targeted monoclonal antibodies, the 5-year survival rates for patients with advanced CRC remain unacceptably low. For patients with colorectal liver metastases, liver resection offers the only potential for cure. This review, based on the outcomes of a meeting of European experts (surgeons and medical oncologists), considers the current treatment strategies available to patients with CRC liver metastases, the criteria for the selection of those patients most likely to benefit and suggests where future progress may occur.

Original languageEnglish
Pages (from-to)65-75
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume72
Issue number1
DOIs
Publication statusPublished - Oct 2009

Keywords

  • Colorectal cancer
  • Disease-free survival
  • Hepatic metastases
  • Neoadjuvant therapy
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy'. Together they form a unique fingerprint.

  • Cite this